# pathway_0074: before and after transfer clarification

[All 1,328 cases](../README.md) · [Method](../METHOD.md) · [Summary](../SUMMARY.md) · [Exact reviewer user message](../inputs/pathway_0074.txt)

**Task:** `pathway`  
**Author key, unchanged:** **D** — Secondary metabolite biosynthesis. .

| Round | Reviewer | Key support | Transfer / lookup | Output usability (canonical status) |
|---|---|---|---|---|
| before | GPT-6 Luna | supported | lookup-dependent | usable output (valid_review) |
| before | Qwen3.8-Flash-Next-NVFP4 | supported | reasoning-supported | usable output (valid_review) |
| after | GPT-6 Luna | supported | reasoning-supported | usable output (valid_review) |
| after | Qwen3.8-Flash-Next-NVFP4 | supported | reasoning-supported | usable output (valid_review) |

**Usable output means format-valid review, not reasoning-supported or biologically correct.** A usable output can classify the question as reasoning-supported, lookup-dependent or uncertain. An output error is a problem with the saved model response; it does not count a defective benchmark question or wrong key. Each saved review is retained in full below. Labels from output errors are displayed as saved and excluded from label statistics. The author key and reviewer evidence were visible to reviewers; this is a review of answerability and key support, not a benchmark-solving score.

## Complete original question

```text
[Protein Sequence]
MPSATPVIPSQQTAIVAEGAGQLSIYHDAPVPALQPDVALVKTAAVAINPVDAKMLDYSPVPGAIHGYDFAGTIVALGSDTPPHLKVGDRVAGFVHGMNPLLPDVGAFAEYVAASADLVLKLPDTMSFEEGASLGLGLFTAGLGLFQHLQIPLSLTREPSPEASSPTKADFVLVAGGSTATGTRALQLLKLAGLRPVATCSPAHFDLARRFGAEAVFDYHDPDCAAAIRAYTKNTLAYALDCLALAETTQLCYGALGRAGGRYVTLEPFREAIAAQRPHTVTPSWLLALTIFGRKVALDGEYGREANPEDREFGARLTEQVQGLLDEGKVDVHPVRVMGGGWQGVLEGVDLVRRQTVSGHKLVYAV

[Multiple Choices]
A. LPS O-antigen biosynthesis. .
B. glycosylphosphatidylinositol-anchor biosynthesis. .
C. L-methionine biosynthesis via de novo pathway. .
D. Secondary metabolite biosynthesis. .
```

<details>
<summary>Complete original system instructions</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Protein Pathway Prediction, which is to predict the primary metabolic or signaling pathway in which a given protein functions. Biological pathways are series of chemical reactions occurring within a cell that are essential for life. Based on the protein's amino acid sequence, you should identify the most relevant pathway from the given options.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## Four saved visible reviews

## Before: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The exact sequence matches the UniProt entry for CaaB, annotated as a trans-enoyl reductase in the carlosic-acid biosynthesis cluster, with the pathway assigned as secondary metabolite biosynthesis. The pathway annotation is transferred by similarity (ECO:0000250), so this supports the key as an annotation but is not, by itself, proof of direct experimental validation for this protein.

Citations as saved: [C1](#evidence-c1), [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence is compatible with a soluble enzyme, but its features do not establish which metabolic pathway it serves. Identifying it as a reductase in a particular fungal biosynthetic cluster requires protein-specific functional or annotation information.


**Missing item-specific fact**

> That this exact protein is CaaB, associated with the carlosic-acid biosynthesis cluster and annotated to secondary metabolite biosynthesis.


**Reason**

> The input supplies only the sequence and broad pathway choices; it does not provide the protein identity, organism, cluster context, or pathway evidence needed to distinguish the specific pathway.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The reviewer-only evidence supports D for this exact sequence. The sequence alone does not distinguish the options, but that lack of supplied evidence does not establish another choice as equally correct.


### Important caveats

- The sequence match applies to the supplied 366-residue sequence.
- The pathway annotation is similarity-transferred; the cited paper concerns acyltetronic-acid derivatives and does not, from the excerpts provided, independently establish direct experimental validation of CaaB's pathway role.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence is compatible with a soluble enzyme, but its features do not establish which metabolic pathway it serves. Identifying it as a reductase in a particular fungal biosynthetic cluster requires protein-specific functional or annotation information.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "That this exact protein is CaaB, associated with the carlosic-acid biosynthesis cluster and annotated to secondary metabolite biosynthesis.",
    "reason": "The input supplies only the sequence and broad pathway choices; it does not provide the protein identity, organism, cluster context, or pathway evidence needed to distinguish the specific pathway."
  },
  "case_id": "pathway_0074",
  "expected_answer_check": {
    "evidence_ids": [
      "C1",
      "C4",
      "C5",
      "C6",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt entry for CaaB, annotated as a trans-enoyl reductase in the carlosic-acid biosynthesis cluster, with the pathway assigned as secondary metabolite biosynthesis. The pathway annotation is transferred by similarity (ECO:0000250), so this supports the key as an annotation but is not, by itself, proof of direct experimental validation for this protein."
  },
  "important_caveats": [
    "The sequence match applies to the supplied 366-residue sequence.",
    "The pathway annotation is similarity-transferred; the cited paper concerns acyltetronic-acid derivatives and does not, from the excerpts provided, independently establish direct experimental validation of CaaB's pathway role."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The reviewer-only evidence supports D for this exact sequence. The sequence alone does not distinguish the options, but that lack of supplied evidence does not establish another choice as equally correct."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0074",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt entry for CaaB, annotated as a trans-enoyl reductase in the carlosic-acid biosynthesis cluster, with the pathway assigned as secondary metabolite biosynthesis. The pathway annotation is transferred by similarity (ECO:0000250), so this supports the key as an annotation but is not, by itself, proof of direct experimental validation for this protein.",
    "evidence_ids": ["C1", "C4", "C5", "C6", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence is compatible with a soluble enzyme, but its features do not establish which metabolic pathway it serves. Identifying it as a reductase in a particular fungal biosynthetic cluster requires protein-specific functional or annotation information.",
    "missing_item_specific_fact": "That this exact protein is CaaB, associated with the carlosic-acid biosynthesis cluster and annotated to secondary metabolite biosynthesis.",
    "reason": "The input supplies only the sequence and broad pathway choices; it does not provide the protein identity, organism, cluster context, or pathway evidence needed to distinguish the specific pathway."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The reviewer-only evidence supports D for this exact sequence. The sequence alone does not distinguish the options, but that lack of supplied evidence does not establish another choice as equally correct."
  },
  "important_caveats": [
    "The sequence match applies to the supplied 366-residue sequence.",
    "The pathway annotation is similarity-transferred; the cited paper concerns acyltetronic-acid derivatives and does not, from the excerpts provided, independently establish direct experimental validation of CaaB's pathway role."
  ]
}
```

</details>

## Before: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> UniProt entry A2QQU5 explicitly annotates the pathway as 'Secondary metabolite biosynthesis' (C5, H3). The protein is Trans-enoyl reductase caaB, part of the carlosic acid biosynthesis cluster in Aspergillus niger. Carlosic acid is a noncanonical cryptic polyketide (a secondary metabolite), confirmed experimentally by PubMed:25044953 (C6, H2). The pathway annotation uses ECO:0000250 (similarity), but the underlying function and pathway are supported by the cited experimental study.

Citations as saved: [C1](#evidence-c1), [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H1](#evidence-h1), [H2](#evidence-h2), [H3](#evidence-h3).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The sequence contains a recognizable NAD(P)-dependent enoyl reductase domain (the 'GGGWQGVLEGVDLVRRQ' region with Rossmann-fold-like architecture and the 'AGGSTATGTRALQ' nucleotide-binding motif). Enoyl reductase domains are hallmark catalytic modules of modular polyketide synthases (PKS), which are the defining enzymes of polyketide (secondary metabolite) biosynthesis in fungi. This distinguishes the protein from primary metabolic reductases: homoserine dehydrogenase in methionine biosynthesis (option C) has a distinct LDH-like fold, and GPI-anchor or LPS biosynthesis enzymes (options A, B) are glycosyltransferases or phosphatases, not NAD(P)-dependent reductases of this architecture. Recognizing the enoyl reductase domain as a PKS component is a standard domain-architecture inference.


**Missing item-specific fact**

> None strictly required; however, the model must correctly identify the enoyl reductase domain architecture and associate it with fungal polyketide synthases rather than other NAD(P)-dependent reductases.


**Reason**

> The sequence provides identifiable domain features (enoyl reductase / NAD(P)-binding motifs) that, through general knowledge of PKS domain organization in fungi, point to secondary metabolite biosynthesis. The distractors represent mechanistically distinct enzyme classes (glycosyltransferases for LPS/GPI, PLP-dependent or LDH-like enzymes for methionine) that do not match the observed domain architecture. This is a legitimate structural-enzymatic inference rather than pure database lookup.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The enoyl reductase domain architecture is specific to polyketide synthases and does not match the enzyme classes involved in LPS O-antigen biosynthesis (glycosyltransferases/polymerases), GPI-anchor biosynthesis (phosphatases/glycosyltransferases), or L-methionine biosynthesis (homoserine dehydrogenase with LDH-like fold, cystathionine gamma-synthase with PLP fold). Only option D is consistent with the observed domain.


### Important caveats

- The UniProt pathway annotation carries ECO:0000250 (inferred by similarity to A0A0E0RXA7), not direct experimental evidence for this specific entry, though the cited PubMed study (25044953) provides experimental confirmation of function and pathway.
- The organism (Aspergillus niger, a fungus) is not stated in the question; however, the enoyl reductase domain reasoning does not strictly require organism knowledge, as enoyl reductase domains are primarily PKS-associated across taxa.
- The reviewer-only evidence was absent from the evaluated model input; the reasoning assessment is based solely on the sequence and choices provided.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence contains a recognizable NAD(P)-dependent enoyl reductase domain (the 'GGGWQGVLEGVDLVRRQ' region with Rossmann-fold-like architecture and the 'AGGSTATGTRALQ' nucleotide-binding motif). Enoyl reductase domains are hallmark catalytic modules of modular polyketide synthases (PKS), which are the defining enzymes of polyketide (secondary metabolite) biosynthesis in fungi. This distinguishes the protein from primary metabolic reductases: homoserine dehydrogenase in methionine biosynthesis (option C) has a distinct LDH-like fold, and GPI-anchor or LPS biosynthesis enzymes (options A, B) are glycosyltransferases or phosphatases, not NAD(P)-dependent reductases of this architecture. Recognizing the enoyl reductase domain as a PKS component is a standard domain-architecture inference.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "None strictly required; however, the model must correctly identify the enoyl reductase domain architecture and associate it with fungal polyketide synthases rather than other NAD(P)-dependent reductases.",
    "reason": "The sequence provides identifiable domain features (enoyl reductase / NAD(P)-binding motifs) that, through general knowledge of PKS domain organization in fungi, point to secondary metabolite biosynthesis. The distractors represent mechanistically distinct enzyme classes (glycosyltransferases for LPS/GPI, PLP-dependent or LDH-like enzymes for methionine) that do not match the observed domain architecture. This is a legitimate structural-enzymatic inference rather than pure database lookup."
  },
  "case_id": "pathway_0074",
  "expected_answer_check": {
    "evidence_ids": [
      "C1",
      "C4",
      "C5",
      "C6",
      "H1",
      "H2",
      "H3"
    ],
    "judgment": "supported",
    "reason": "UniProt entry A2QQU5 explicitly annotates the pathway as 'Secondary metabolite biosynthesis' (C5, H3). The protein is Trans-enoyl reductase caaB, part of the carlosic acid biosynthesis cluster in Aspergillus niger. Carlosic acid is a noncanonical cryptic polyketide (a secondary metabolite), confirmed experimentally by PubMed:25044953 (C6, H2). The pathway annotation uses ECO:0000250 (similarity), but the underlying function and pathway are supported by the cited experimental study."
  },
  "important_caveats": [
    "The UniProt pathway annotation carries ECO:0000250 (inferred by similarity to A0A0E0RXA7), not direct experimental evidence for this specific entry, though the cited PubMed study (25044953) provides experimental confirmation of function and pathway.",
    "The organism (Aspergillus niger, a fungus) is not stated in the question; however, the enoyl reductase domain reasoning does not strictly require organism knowledge, as enoyl reductase domains are primarily PKS-associated across taxa.",
    "The reviewer-only evidence was absent from the evaluated model input; the reasoning assessment is based solely on the sequence and choices provided."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The enoyl reductase domain architecture is specific to polyketide synthases and does not match the enzyme classes involved in LPS O-antigen biosynthesis (glycosyltransferases/polymerases), GPI-anchor biosynthesis (phosphatases/glycosyltransferases), or L-methionine biosynthesis (homoserine dehydrogenase with LDH-like fold, cystathionine gamma-synthase with PLP fold). Only option D is consistent with the observed domain."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0074",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "UniProt entry A2QQU5 explicitly annotates the pathway as 'Secondary metabolite biosynthesis' (C5, H3). The protein is Trans-enoyl reductase caaB, part of the carlosic acid biosynthesis cluster in Aspergillus niger. Carlosic acid is a noncanonical cryptic polyketide (a secondary metabolite), confirmed experimentally by PubMed:25044953 (C6, H2). The pathway annotation uses ECO:0000250 (similarity), but the underlying function and pathway are supported by the cited experimental study.",
    "evidence_ids": ["C1", "C4", "C5", "C6", "H1", "H2", "H3"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The sequence contains a recognizable NAD(P)-dependent enoyl reductase domain (the 'GGGWQGVLEGVDLVRRQ' region with Rossmann-fold-like architecture and the 'AGGSTATGTRALQ' nucleotide-binding motif). Enoyl reductase domains are hallmark catalytic modules of modular polyketide synthases (PKS), which are the defining enzymes of polyketide (secondary metabolite) biosynthesis in fungi. This distinguishes the protein from primary metabolic reductases: homoserine dehydrogenase in methionine biosynthesis (option C) has a distinct LDH-like fold, and GPI-anchor or LPS biosynthesis enzymes (options A, B) are glycosyltransferases or phosphatases, not NAD(P)-dependent reductases of this architecture. Recognizing the enoyl reductase domain as a PKS component is a standard domain-architecture inference.",
    "missing_item_specific_fact": "None strictly required; however, the model must correctly identify the enoyl reductase domain architecture and associate it with fungal polyketide synthases rather than other NAD(P)-dependent reductases.",
    "reason": "The sequence provides identifiable domain features (enoyl reductase / NAD(P)-binding motifs) that, through general knowledge of PKS domain organization in fungi, point to secondary metabolite biosynthesis. The distractors represent mechanistically distinct enzyme classes (glycosyltransferases for LPS/GPI, PLP-dependent or LDH-like enzymes for methionine) that do not match the observed domain architecture. This is a legitimate structural-enzymatic inference rather than pure database lookup."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The enoyl reductase domain architecture is specific to polyketide synthases and does not match the enzyme classes involved in LPS O-antigen biosynthesis (glycosyltransferases/polymerases), GPI-anchor biosynthesis (phosphatases/glycosyltransferases), or L-methionine biosynthesis (homoserine dehydrogenase with LDH-like fold, cystathionine gamma-synthase with PLP fold). Only option D is consistent with the observed domain."
  },
  "important_caveats": [
    "The UniProt pathway annotation carries ECO:0000250 (inferred by similarity to A0A0E0RXA7), not direct experimental evidence for this specific entry, though the cited PubMed study (25044953) provides experimental confirmation of function and pathway.",
    "The organism (Aspergillus niger, a fungus) is not stated in the question; however, the enoyl reductase domain reasoning does not strictly require organism knowledge, as enoyl reductase domains are primarily PKS-associated across taxa.",
    "The reviewer-only evidence was absent from the evaluated model input; the reasoning assessment is based solely on the sequence and choices provided."
  ]
}
```

</details>

## After: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The sequence-matched archived UniProt record assigns the protein to secondary metabolite biosynthesis. That pathway annotation is transferred from another UniProt protein (ECO:0000250), so it supports the key as a database annotation rather than as direct experimental confirmation for this exact protein.

Citations as saved: [H3](#evidence-h3).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The sequence is a compact soluble enzyme and has a glycine-rich region (including “AIVAEGAG”) compatible with a nucleotide-binding reductase. Enoyl-reduction enzymes can participate in natural-product biosynthesis; that enzyme class and soluble architecture make secondary-metabolite biosynthesis a credible choice over LPS O-antigen or GPI-anchor biosynthesis, which involve glycan or membrane-associated machinery, and over the specifically named methionine pathway. This is a probabilistic inference, not a pathway identification from a unique motif.


**Missing item-specific fact**

Empty string, as saved.


**Reason**

> Transferable sequence and enzyme-family knowledge provides a meaningful, if limited, basis for preferring D among these choices. The sequence alone does not establish the enzyme’s pathway context, and reductases can also function in primary metabolism, so genomic context would strengthen the inference.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> No other offered option is as defensible from the sequence-level inference, though the pathway assignment is not uniquely established by sequence features.


### Important caveats

- The pathway annotation in the supplied source is explicitly transferred by similarity; it is not direct experimental evidence for this sequence.
- The original input provides no organism or gene-cluster context.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence is a compact soluble enzyme and has a glycine-rich region (including “AIVAEGAG”) compatible with a nucleotide-binding reductase. Enoyl-reduction enzymes can participate in natural-product biosynthesis; that enzyme class and soluble architecture make secondary-metabolite biosynthesis a credible choice over LPS O-antigen or GPI-anchor biosynthesis, which involve glycan or membrane-associated machinery, and over the specifically named methionine pathway. This is a probabilistic inference, not a pathway identification from a unique motif.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "",
    "reason": "Transferable sequence and enzyme-family knowledge provides a meaningful, if limited, basis for preferring D among these choices. The sequence alone does not establish the enzyme’s pathway context, and reductases can also function in primary metabolism, so genomic context would strengthen the inference."
  },
  "case_id": "pathway_0074",
  "expected_answer_check": {
    "evidence_ids": [
      "H3"
    ],
    "judgment": "supported",
    "reason": "The sequence-matched archived UniProt record assigns the protein to secondary metabolite biosynthesis. That pathway annotation is transferred from another UniProt protein (ECO:0000250), so it supports the key as a database annotation rather than as direct experimental confirmation for this exact protein."
  },
  "important_caveats": [
    "The pathway annotation in the supplied source is explicitly transferred by similarity; it is not direct experimental evidence for this sequence.",
    "The original input provides no organism or gene-cluster context."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "No other offered option is as defensible from the sequence-level inference, though the pathway assignment is not uniquely established by sequence features."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0074",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The sequence-matched archived UniProt record assigns the protein to secondary metabolite biosynthesis. That pathway annotation is transferred from another UniProt protein (ECO:0000250), so it supports the key as a database annotation rather than as direct experimental confirmation for this exact protein.",
    "evidence_ids": ["H3"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The sequence is a compact soluble enzyme and has a glycine-rich region (including “AIVAEGAG”) compatible with a nucleotide-binding reductase. Enoyl-reduction enzymes can participate in natural-product biosynthesis; that enzyme class and soluble architecture make secondary-metabolite biosynthesis a credible choice over LPS O-antigen or GPI-anchor biosynthesis, which involve glycan or membrane-associated machinery, and over the specifically named methionine pathway. This is a probabilistic inference, not a pathway identification from a unique motif.",
    "missing_item_specific_fact": "",
    "reason": "Transferable sequence and enzyme-family knowledge provides a meaningful, if limited, basis for preferring D among these choices. The sequence alone does not establish the enzyme’s pathway context, and reductases can also function in primary metabolism, so genomic context would strengthen the inference."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "No other offered option is as defensible from the sequence-level inference, though the pathway assignment is not uniquely established by sequence features."
  },
  "important_caveats": [
    "The pathway annotation in the supplied source is explicitly transferred by similarity; it is not direct experimental evidence for this sequence.",
    "The original input provides no organism or gene-cluster context."
  ]
}
```

</details>

## After: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt entry (A2QQU5) annotates this protein with pathway 'Secondary metabolite biosynthesis' (ECO:0000250, inferred by similarity to A0A0E0RXA7). The protein is named 'Trans-enoyl reductase caaB' / 'Carlosic acid biosynthesis cluster protein B,' and carlosic acid is described as a noncanonical cryptic polyketide from Aspergillus niger (PubMed:25044953). Polyketides are classic fungal secondary metabolites, so the pathway assignment is biologically coherent. The pathway comment itself is by similarity (ECO:0000250), but the protein's function as a trans-enoyl reductase in a polyketide biosynthetic cluster is experimentally supported (ECO:0000269 for EC, and the reference paper provides FUNCTION, CATALYTIC ACTIVITY, INDUCTION, and PATHWAY data).

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H3](#evidence-h3).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The sequence contains a Rossmann-fold-like nucleotide-binding motif (GxGxxG pattern visible in 'VAGGSTATGTRALQ' and 'GGGWQGVLEGVDLVRRQ'), characteristic of an NAD(P)-dependent reductase. Among the four options: (A) LPS O-antigen biosynthesis involves glycosyltransferases, polymerases, and specific transferases — not NAD(P)-dependent reductases with this architecture; (B) GPI-anchor biosynthesis involves phosphatases, glycosyltransferases, and transamidases — again not a reductase of this type; (C) L-methionine de novo biosynthesis involves homoserine dehydrogenase (a different reductase family with distinct domain organization), cystathionine synthases, and related enzymes — the domain architecture here does not match these; (D) Secondary metabolite (polyketide) biosynthesis clusters in fungi routinely encode NADPH-dependent trans-enoyl reductases as tailoring enzymes, and the observed reductase domain architecture is consistent with this family. A knowledgeable model can eliminate A and B based on the absence of glycosyltransferase/transferase features, and distinguish C from D by recognizing that the specific reductase domain architecture aligns with polyketide-cluster enoyl reductases rather than amino-acid-biosynthesis dehydrogenases.


**Missing item-specific fact**

Empty string, as saved.


**Reason**

> The domain architecture (NAD(P)-binding Rossmann fold consistent with a reductase) combined with knowledge of enzyme families in each pathway allows meaningful discrimination. Glycosyltransferase/polymerase enzymes (A, B) are structurally distinct. The specific reductase architecture is more consistent with polyketide tailoring enzymes (D) than with homoserine dehydrogenase or methionine-pathway enzymes (C). This is a family-level inference from transferable knowledge of enzyme domain architectures across pathways.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> While 'Secondary metabolite biosynthesis' is a broad category, the four options are sufficiently distinct in the types of enzymes they involve. The reductase domain architecture does not match glycosyltransferases (A, B) or the specific enzymes of methionine biosynthesis (C). No other option is equally defensible given the domain architecture.


### Important caveats

- The UniProt pathway annotation carries evidence code ECO:0000250 (inferred by similarity), not direct experimental pathway proof for this exact protein, though the protein's function and catalytic activity are experimentally supported.
- 'Secondary metabolite biosynthesis' is a very broad pathway category; the specific sub-pathway is polyketide (carlosic acid) biosynthesis, but the question only asks at the broad level.
- The organism (Aspergillus niger) is not given to the model, but the reasoning does not require knowing the organism — the domain architecture alone distinguishes the options.
- The sequence is 366 aa and contains a reductase domain; a model unfamiliar with trans-enoyl reductase domain architecture in polyketide clusters might struggle to definitively exclude option C, though the domain organizations are distinguishable.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence contains a Rossmann-fold-like nucleotide-binding motif (GxGxxG pattern visible in 'VAGGSTATGTRALQ' and 'GGGWQGVLEGVDLVRRQ'), characteristic of an NAD(P)-dependent reductase. Among the four options: (A) LPS O-antigen biosynthesis involves glycosyltransferases, polymerases, and specific transferases — not NAD(P)-dependent reductases with this architecture; (B) GPI-anchor biosynthesis involves phosphatases, glycosyltransferases, and transamidases — again not a reductase of this type; (C) L-methionine de novo biosynthesis involves homoserine dehydrogenase (a different reductase family with distinct domain organization), cystathionine synthases, and related enzymes — the domain architecture here does not match these; (D) Secondary metabolite (polyketide) biosynthesis clusters in fungi routinely encode NADPH-dependent trans-enoyl reductases as tailoring enzymes, and the observed reductase domain architecture is consistent with this family. A knowledgeable model can eliminate A and B based on the absence of glycosyltransferase/transferase features, and distinguish C from D by recognizing that the specific reductase domain architecture aligns with polyketide-cluster enoyl reductases rather than amino-acid-biosynthesis dehydrogenases.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "",
    "reason": "The domain architecture (NAD(P)-binding Rossmann fold consistent with a reductase) combined with knowledge of enzyme families in each pathway allows meaningful discrimination. Glycosyltransferase/polymerase enzymes (A, B) are structurally distinct. The specific reductase architecture is more consistent with polyketide tailoring enzymes (D) than with homoserine dehydrogenase or methionine-pathway enzymes (C). This is a family-level inference from transferable knowledge of enzyme domain architectures across pathways."
  },
  "case_id": "pathway_0074",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5",
      "C6",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The UniProt entry (A2QQU5) annotates this protein with pathway 'Secondary metabolite biosynthesis' (ECO:0000250, inferred by similarity to A0A0E0RXA7). The protein is named 'Trans-enoyl reductase caaB' / 'Carlosic acid biosynthesis cluster protein B,' and carlosic acid is described as a noncanonical cryptic polyketide from Aspergillus niger (PubMed:25044953). Polyketides are classic fungal secondary metabolites, so the pathway assignment is biologically coherent. The pathway comment itself is by similarity (ECO:0000250), but the protein's function as a trans-enoyl reductase in a polyketide biosynthetic cluster is experimentally supported (ECO:0000269 for EC, and the reference paper provides FUNCTION, CATALYTIC ACTIVITY, INDUCTION, and PATHWAY data)."
  },
  "important_caveats": [
    "The UniProt pathway annotation carries evidence code ECO:0000250 (inferred by similarity), not direct experimental pathway proof for this exact protein, though the protein's function and catalytic activity are experimentally supported.",
    "'Secondary metabolite biosynthesis' is a very broad pathway category; the specific sub-pathway is polyketide (carlosic acid) biosynthesis, but the question only asks at the broad level.",
    "The organism (Aspergillus niger) is not given to the model, but the reasoning does not require knowing the organism — the domain architecture alone distinguishes the options.",
    "The sequence is 366 aa and contains a reductase domain; a model unfamiliar with trans-enoyl reductase domain architecture in polyketide clusters might struggle to definitively exclude option C, though the domain organizations are distinguishable."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "While 'Secondary metabolite biosynthesis' is a broad category, the four options are sufficiently distinct in the types of enzymes they involve. The reductase domain architecture does not match glycosyltransferases (A, B) or the specific enzymes of methionine biosynthesis (C). No other option is equally defensible given the domain architecture."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0074",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt entry (A2QQU5) annotates this protein with pathway 'Secondary metabolite biosynthesis' (ECO:0000250, inferred by similarity to A0A0E0RXA7). The protein is named 'Trans-enoyl reductase caaB' / 'Carlosic acid biosynthesis cluster protein B,' and carlosic acid is described as a noncanonical cryptic polyketide from Aspergillus niger (PubMed:25044953). Polyketides are classic fungal secondary metabolites, so the pathway assignment is biologically coherent. The pathway comment itself is by similarity (ECO:0000250), but the protein's function as a trans-enoyl reductase in a polyketide biosynthetic cluster is experimentally supported (ECO:0000269 for EC, and the reference paper provides FUNCTION, CATALYTIC ACTIVITY, INDUCTION, and PATHWAY data).",
    "evidence_ids": ["C4", "C5", "C6", "H3"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The sequence contains a Rossmann-fold-like nucleotide-binding motif (GxGxxG pattern visible in 'VAGGSTATGTRALQ' and 'GGGWQGVLEGVDLVRRQ'), characteristic of an NAD(P)-dependent reductase. Among the four options: (A) LPS O-antigen biosynthesis involves glycosyltransferases, polymerases, and specific transferases — not NAD(P)-dependent reductases with this architecture; (B) GPI-anchor biosynthesis involves phosphatases, glycosyltransferases, and transamidases — again not a reductase of this type; (C) L-methionine de novo biosynthesis involves homoserine dehydrogenase (a different reductase family with distinct domain organization), cystathionine synthases, and related enzymes — the domain architecture here does not match these; (D) Secondary metabolite (polyketide) biosynthesis clusters in fungi routinely encode NADPH-dependent trans-enoyl reductases as tailoring enzymes, and the observed reductase domain architecture is consistent with this family. A knowledgeable model can eliminate A and B based on the absence of glycosyltransferase/transferase features, and distinguish C from D by recognizing that the specific reductase domain architecture aligns with polyketide-cluster enoyl reductases rather than amino-acid-biosynthesis dehydrogenases.",
    "missing_item_specific_fact": "",
    "reason": "The domain architecture (NAD(P)-binding Rossmann fold consistent with a reductase) combined with knowledge of enzyme families in each pathway allows meaningful discrimination. Glycosyltransferase/polymerase enzymes (A, B) are structurally distinct. The specific reductase architecture is more consistent with polyketide tailoring enzymes (D) than with homoserine dehydrogenase or methionine-pathway enzymes (C). This is a family-level inference from transferable knowledge of enzyme domain architectures across pathways."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "While 'Secondary metabolite biosynthesis' is a broad category, the four options are sufficiently distinct in the types of enzymes they involve. The reductase domain architecture does not match glycosyltransferases (A, B) or the specific enzymes of methionine biosynthesis (C). No other option is equally defensible given the domain architecture."
  },
  "important_caveats": [
    "The UniProt pathway annotation carries evidence code ECO:0000250 (inferred by similarity), not direct experimental pathway proof for this exact protein, though the protein's function and catalytic activity are experimentally supported.",
    "'Secondary metabolite biosynthesis' is a very broad pathway category; the specific sub-pathway is polyketide (carlosic acid) biosynthesis, but the question only asks at the broad level.",
    "The organism (Aspergillus niger) is not given to the model, but the reasoning does not require knowing the organism — the domain architecture alone distinguishes the options.",
    "The sequence is 366 aa and contains a reductase domain; a model unfamiliar with trans-enoyl reductase domain architecture in polyketide clusters might struggle to definitively exclude option C, though the domain organizations are distinguishable."
  ]
}
```

</details>

## Existing project source checks of the old Luna review only

These unchanged notes concern the earlier Luna claims. They do not validate either new review or the old Qwen review. No new scientific adjudication was performed.

## Project source-check notes

These project-authored, AI-assisted checks assess specific source claims. They are not expert adjudication and do not replace Luna’s saved review or the author key.

No additional case-specific project note was recorded. Citation membership checks do not establish that every scientific argument is correct.

## Complete reviewer-only evidence and qualifications

All excerpts supplied in the original and revised reviewer user message follow. This material was not available to the original evaluated model. Accession identity came from dataset image-path metadata. Source support and transferable discrimination are separate judgments.

**Applicability metadata, unchanged:**

```json
{
  "requested_accession": "A2QQU5",
  "identity_origin": "reviewer-only accession inferred mechanically from original dataset image-path metadata; this accession/metadata was absent from evaluated model input",
  "benchmark_sequence_sha256": "e8c47c98be4b92604db479b0e043223ec279e935102532b224ab7194cb91d5c6",
  "benchmark_sequence_length": 366,
  "current_status": "retrieved",
  "current_sequence_comparison": "matched",
  "current_entry_audit": {
    "entryVersion": 101,
    "firstPublicDate": "2025-04-09",
    "lastAnnotationUpdateDate": "2026-09-02",
    "lastSequenceUpdateDate": "2007-03-06",
    "sequenceVersion": 1
  },
  "current_uniprot_release": "2026_03",
  "current_record_sha256": "ec0720d681f22d21e385e54c1260725a15cf2c30e21daab42ba29c923141a8dd",
  "current_source_sequence_sha256": "e8c47c98be4b92604db479b0e043223ec279e935102532b224ab7194cb91d5c6",
  "current_source_sequence_length": 366,
  "historical_status": "retrieved",
  "historical_cutoff_date": "2026-05-07",
  "historical_sequence_comparison": "matched",
  "selected_historical_entry_version": 100,
  "selected_historical_version": {
    "accession": "A2QQU5",
    "database": "Swiss-Prot",
    "entryVersion": 100,
    "firstRelease": "2026_01/2026_01",
    "firstReleaseDate": "28-Jan-2026",
    "lastRelease": "2026_02/2026_02",
    "lastReleaseDate": "10-Jun-2026",
    "name": "CAAB_ASPNC",
    "sequenceVersion": 1
  },
  "selected_historical_record_sha256": "1d9df0690710a301b1081da4f1701485317bbf1008a1422094bc639434427cf1",
  "selected_historical_source_sequence_sha256": "e8c47c98be4b92604db479b0e043223ec279e935102532b224ab7194cb91d5c6",
  "selected_historical_source_sequence_length": 366,
  "latest_at_cutoff_sequence_comparison": "matched",
  "historical_sequence_versions_checked": [
    {
      "entry_version": 100,
      "exact_sequence_comparison": "matched",
      "sequence_version": 1
    }
  ],
  "actual_author_source_snapshot": "unknown",
  "numbering": "Canonical entry coordinates; construct or isoform numbering is not assumed."
}
```

**Qualifications, unchanged:**

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.

### Evidence C1

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A2QQU5.json)

```json
{
  "evidence_id": "C1",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A2QQU5.json",
  "source_sha256": "ec0720d681f22d21e385e54c1260725a15cf2c30e21daab42ba29c923141a8dd",
  "retrieved_utc": "2026-11-02T04:26:50.908499+00:00",
  "json_pointer": "/primaryAccession",
  "excerpt": "\"A2QQU5\"",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C2

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A2QQU5.json)

```json
{
  "evidence_id": "C2",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A2QQU5.json",
  "source_sha256": "ec0720d681f22d21e385e54c1260725a15cf2c30e21daab42ba29c923141a8dd",
  "retrieved_utc": "2026-11-02T04:26:50.908499+00:00",
  "json_pointer": "/entryAudit",
  "excerpt": "{\"entryVersion\":101,\"firstPublicDate\":\"2025-04-09\",\"lastAnnotationUpdateDate\":\"2026-09-02\",\"lastSequenceUpdateDate\":\"2007-03-06\",\"sequenceVersion\":1}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C3

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A2QQU5.json)

```json
{
  "evidence_id": "C3",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A2QQU5.json",
  "source_sha256": "ec0720d681f22d21e385e54c1260725a15cf2c30e21daab42ba29c923141a8dd",
  "retrieved_utc": "2026-11-02T04:26:50.908499+00:00",
  "json_pointer": "/organism",
  "excerpt": "{\"lineage\":[\"Eukaryota\",\"Fungi\",\"Dikarya\",\"Ascomycota\",\"Pezizomycotina\",\"Eurotiomycetes\",\"Eurotiomycetidae\",\"Eurotiales\",\"Aspergillaceae\",\"Aspergillus\",\"Circumdati\"],\"scientificName\":\"Aspergillus niger (strain ATCC MYA-4892 / CBS 513.88 / FGSC A1513)\",\"taxonId\":425011}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C4

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A2QQU5.json)

```json
{
  "evidence_id": "C4",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A2QQU5.json",
  "source_sha256": "ec0720d681f22d21e385e54c1260725a15cf2c30e21daab42ba29c923141a8dd",
  "retrieved_utc": "2026-11-02T04:26:50.908499+00:00",
  "json_pointer": "/proteinDescription",
  "excerpt": "{\"alternativeNames\":[{\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"25044953\",\"source\":\"PubMed\"}],\"value\":\"Carlosic acid biosynthesis cluster protein B\"}}],\"recommendedName\":{\"ecNumbers\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000269\",\"id\":\"25044953\",\"source\":\"PubMed\"}],\"value\":\"1.-.-.-\"}],\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"25044953\",\"source\":\"PubMed\"}],\"value\":\"Trans-enoyl reductase caaB\"}}}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C5

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A2QQU5.json)

```json
{
  "evidence_id": "C5",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A2QQU5.json",
  "source_sha256": "ec0720d681f22d21e385e54c1260725a15cf2c30e21daab42ba29c923141a8dd",
  "retrieved_utc": "2026-11-02T04:26:50.908499+00:00",
  "json_pointer": "/comments/1",
  "excerpt": "{\"commentType\":\"PATHWAY\",\"texts\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000250\",\"id\":\"A0A0E0RXA7\",\"source\":\"UniProtKB\"}],\"value\":\"Secondary metabolite biosynthesis\"}]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A2QQU5.json)

```json
{
  "evidence_id": "C6",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A2QQU5.json",
  "source_sha256": "ec0720d681f22d21e385e54c1260725a15cf2c30e21daab42ba29c923141a8dd",
  "retrieved_utc": "2026-11-02T04:26:50.908499+00:00",
  "json_pointer": "/references/1",
  "excerpt": "{\"citation\":{\"authors\":[\"Yang X.L.\",\"Awakawa T.\",\"Wakimoto T.\",\"Abe I.\"],\"citationCrossReferences\":[{\"database\":\"PubMed\",\"id\":\"25044953\"},{\"database\":\"DOI\",\"id\":\"10.1002/cbic.201402172\"}],\"citationType\":\"journal article\",\"firstPage\":\"1578\",\"id\":\"25044953\",\"journal\":\"ChemBioChem\",\"lastPage\":\"1583\",\"publicationDate\":\"2014\",\"title\":\"Three acyltetronic acid derivatives: noncanonical cryptic polyketides from Aspergillus niger identified by genome mining.\",\"volume\":\"15\"},\"referenceNumber\":2,\"referencePositions\":[\"FUNCTION\",\"CATALYTIC ACTIVITY\",\"INDUCTION\",\"PATHWAY\"]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence H1

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A2QQU5?format=txt&versions=100)

```json
{
  "evidence_id": "H1",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A2QQU5?format=txt&versions=100",
  "source_sha256": "1d9df0690710a301b1081da4f1701485317bbf1008a1422094bc639434427cf1",
  "retrieved_utc": "2026-11-02T04:26:55.145395+00:00",
  "source_locator": "lines 1-14",
  "excerpt": "ID   CAAB_ASPNC              Reviewed;         366 AA.\nAC   A2QQU5;\nDT   09-APR-2025, integrated into UniProtKB/Swiss-Prot.\nDT   06-MAR-2007, sequence version 1.\nDT   28-JAN-2026, entry version 100.\nDE   RecName: Full=Trans-enoyl reductase caaB {ECO:0000303|PubMed:25044953};\nDE            EC=1.-.-.- {ECO:0000269|PubMed:25044953};\nDE   AltName: Full=Carlosic acid biosynthesis cluster protein B {ECO:0000303|PubMed:25044953};\nGN   Name=caaB {ECO:0000303|PubMed:25044953}; ORFNames=An08g03740;\nOS   Aspergillus niger (strain ATCC MYA-4892 / CBS 513.88 / FGSC A1513).\nOC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Eurotiomycetes;\nOC   Eurotiomycetidae; Eurotiales; Aspergillaceae; Aspergillus;\nOC   Aspergillus subgen. Circumdati.\nOX   NCBI_TaxID=425011;\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 100,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H2

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A2QQU5?format=txt&versions=100)

```json
{
  "evidence_id": "H2",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A2QQU5?format=txt&versions=100",
  "source_sha256": "1d9df0690710a301b1081da4f1701485317bbf1008a1422094bc639434427cf1",
  "retrieved_utc": "2026-11-02T04:26:55.145395+00:00",
  "source_locator": "lines 36-42",
  "excerpt": "RN   [2]\nRP   FUNCTION, CATALYTIC ACTIVITY, INDUCTION, AND PATHWAY.\nRX   PubMed=25044953; DOI=10.1002/cbic.201402172;\nRA   Yang X.L., Awakawa T., Wakimoto T., Abe I.;\nRT   \"Three acyltetronic acid derivatives: noncanonical cryptic polyketides from\nRT   Aspergillus niger identified by genome mining.\";\nRL   ChemBioChem 15:1578-1583(2014).\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 100,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A2QQU5?format=txt&versions=100)

```json
{
  "evidence_id": "H3",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A2QQU5?format=txt&versions=100",
  "source_sha256": "1d9df0690710a301b1081da4f1701485317bbf1008a1422094bc639434427cf1",
  "retrieved_utc": "2026-11-02T04:26:55.145395+00:00",
  "source_locator": "lines 62-63",
  "excerpt": "CC   -!- PATHWAY: Secondary metabolite biosynthesis.\nCC       {ECO:0000250|UniProtKB:A0A0E0RXA7}.\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 100,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/pathway.json), zero-based source row 74. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). [Source credits](../THIRD_PARTY_NOTICES.md).
